| Abstrakt: |
Schizophrenia is a chronic brain condition that affects roughly 1% of the world's population and causes delusions, hallucinations, disorganized speech, mental difficulties, and a lack of motivation while it is active. Despite the fact that treatment, especially drug therapy, has been widely used for nearly a century, there is no evidence that it has improved the majority of people with schizophrenia. Current adverse effects may be better if we view schizophrenia as a developmental disorder with psychosis as a stage of delayed illness. This ‘rethinking’ of schizophrenia as a neurodevelopment disorder, very different from the way we thought about illness in the last century, has great potential for prevention and treatment over the next two decades. Conclusion: Most people with schizophrenia benefit from a combination of antimicrobials and non-pharmacologic treatments designed for their specific needs. The provision of low-dose antipsychotic drugs, monitoring and resolving side effects, and providing clozapine if patients continue to have psychiatric symptoms are the norm for medical treatment. Several promising ways to improve outcomes in schizophrenia are being investigated, including glutamate-N-methyld-aspartate (NMDA) cascade drugs, which can help patients with chronic disease reduce persistent psychiatric symptoms, symptoms, and dementia. |
